These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Small-molecule oligonucleotides as smart modality for antiviral therapy: a medicinal chemistry perspective. Kar SS; Dhar AK; Palei NN; Bhatt S Future Med Chem; 2023 Jun; 15(12):1091-1110. PubMed ID: 37584172 [TBL] [Abstract][Full Text] [Related]
26. Advances in oligonucleotide drug delivery. Roberts TC; Langer R; Wood MJA Nat Rev Drug Discov; 2020 Oct; 19(10):673-694. PubMed ID: 32782413 [TBL] [Abstract][Full Text] [Related]
27. Drug delivery of oligonucleotides by peptides. Lochmann D; Jauk E; Zimmer A Eur J Pharm Biopharm; 2004 Sep; 58(2):237-51. PubMed ID: 15296952 [TBL] [Abstract][Full Text] [Related]
28. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany. Uhlmann E Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539 [TBL] [Abstract][Full Text] [Related]
29. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117 [TBL] [Abstract][Full Text] [Related]
30. Nanotechnology and aptamers: applications in drug delivery. Levy-Nissenbaum E; Radovic-Moreno AF; Wang AZ; Langer R; Farokhzad OC Trends Biotechnol; 2008 Aug; 26(8):442-9. PubMed ID: 18571753 [TBL] [Abstract][Full Text] [Related]
31. Water-soluble, meso-substituted cationic porphyrins--a family of compounds for cellular delivery of oligonucleotides. Flynn SM; George ST; White L; Devonish W; Takle GB Biotechniques; 1999 Apr; 26(4):736-42, 744, 746. PubMed ID: 10343913 [TBL] [Abstract][Full Text] [Related]
32. Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting. Scheicher B; Schachner-Nedherer AL; Zimmer A Eur J Pharm Sci; 2015 Jul; 75():54-9. PubMed ID: 25896372 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Goga A; Stoffel M Nat Rev Drug Discov; 2022 Jun; 21(6):417-439. PubMed ID: 35210608 [TBL] [Abstract][Full Text] [Related]
34. Oligonucleotide delivery in cancer therapy. De Rosa G; De Stefano D; Galeone A Expert Opin Drug Deliv; 2010 Nov; 7(11):1263-78. PubMed ID: 20977291 [TBL] [Abstract][Full Text] [Related]
35. [Study toward practical use of oligonucleotide therapeutics]. Inoue T; Yoshida T Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):13-5. PubMed ID: 25707197 [TBL] [Abstract][Full Text] [Related]
37. Strategies for designing clinical trials for oligonucleotide therapeutics. Wacheck V Drug Discov Today; 2004 Nov; 9(21):918-23. PubMed ID: 15501726 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic oligonucleotides and delivery technologies: Research topics in Japan. Murakami M Drug Discov Ther; 2016; 10(5):234-235. PubMed ID: 27890898 [TBL] [Abstract][Full Text] [Related]
39. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Campbell MA; Wengel J Chem Soc Rev; 2011 Dec; 40(12):5680-9. PubMed ID: 21556437 [TBL] [Abstract][Full Text] [Related]